Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended September 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	9,116			$	—			$	—			$	9,116
Grant and other revenue			87,266				—				—				87,266
Total revenue			96,382				—				—				96,382
Research and development expenses			906,677				142,109				—				1,048,786
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				744				1,450,565				1,451,309
Depreciation and amortization ⁽²⁾			6,040				—				12,026				18,066
Loss from operations ⁽³⁾			(816,335	)			(142,853	)			(1,462,591	)			(2,421,779	)
Other expense ⁽⁴⁾			—				—				(14	)			(14	)
Income tax expense			(5,763	)			(824	)			(9,457	)			(16,043	)
Net loss			(822,098	)			(143,677	)			(1,472,062	)			(2,437,836	)
Total assets, net of depreciation and amortization:
United States		$	185,205			$	—			$	8,557,398			$	8,742,603
International			216,353				—				590				216,943
Capital expenditures			—				—				18,042				18,042

Three Months Ended September 30, 2020		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	2,047			$	—			$	—			$	2,047
License revenue			4,726				—				—				4,726
Grant and other revenue			106,729				154,887				—				261,616
Total revenue			113,502				154,887				—				268,389
Cost of revenue			82				—				—				82
Research and development expenses			1,251,383				126,615				—				1,377,998
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				—				1,773,532				1,773,532
Depreciation and amortization ⁽²⁾			4,027				—				11,375				15,402
(Loss) income from operations ⁽³⁾			(1,268,605	)			28,272				(1,784,907	)			(2,898,625	)
Other expense ⁽⁴⁾			—				—				(713	)			(713	)
Net (loss) income			(1,141,990	)			28,272				(1,785,620	)			(2,899,338	)
Total assets, net of depreciation and amortization:
United States		$	1,000			$	38,320			$	5,839,733			$	5,879,053
International			116,782				—				—				116,782
Capital expenditures			120,810				—				—				120,810

Nine Months Ended September 30, 2021		Diagnostics				Therapeutics				Corporate				Total
License revenue		$	44,665			$	—			$	—			$	44,665
Grant and other revenue			436,500				—				—				436,500
Total revenue			481,165				—				—				481,165
Research and development expenses			3,359,190				410,406				—				3,769,596
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				3,623				5,073,435				5,077,058
Depreciation and amortization ⁽²⁾			18,121				—				37,551				55,672
Loss from operations ⁽³⁾			(2,896,146	)			(414,029	)			(5,110,986	)			(8,421,161	)
Other income ⁽⁴⁾			—				—				358,436				358,436
Income tax expense			(5,763	)			(824	)			(9,457	)			(16,043	)
Net loss			(2,901,909	)			(414,853	)			(4,762,007	)			(8,078,768	)
Total assets, net of depreciation and amortization:
United States		$	185,205			$	—			$	8,557,398			$	8,742,603
International			216,353				—				590				216,943
Capital expenditures			—				—				20,749				20,749

Nine Months Ended September 30, 2020		Diagnostics				Therapeutics				Corporate				Total
Royalty revenue		$	26,188			$	—			$	—			$	26,188
License revenue			4,726				—				—				4,726
Grant and other revenue			381,103				283,745				—				664,848
Total revenue			412,017				283,745				—				695,762
Cost of revenue			1,048				—				—				1,048
Research and development expenses			3,402,160				256,886				—				3,659,046
Selling, general and administrative expenses, excluding depreciation and amortization ⁽¹⁾			—				(550	)			4,895,328				4,894,778
Depreciation and amortization ⁽²⁾			4,027				—				47,474				51,501
(Loss) income from operations ⁽³⁾			(2,995,218	)			27,409				(4,942,802	)			(7,910,611	)
Other income ⁽⁴⁾			—				—				12,045				12,045
Net (loss) income			(2,995,218	)			27,409				(4,930,757	)			(7,898,566	)
Total assets, net of depreciation and amortization:
United States		$	1,000			$	38,320			$	5,839,733			$	5,879,053
International			116,782				—				—				116,782
Capital expenditures			120,810				—				8,406				129,216